Oxford Science Enterprises collects $300M to offer spinouts 'scale-up capital'

Amber Tong

Senior Editor

For the past seven years, biotech spinouts from the University of Oxford have often tapped into a reliable source of investments from Oxford Science Enterprises, the company tasked with founding, funding and building startups based on “exceptional science” flowing out of Oxford.

And the pool has gotten $300 million (£250 million) deeper as Oxford Science Enterprises bags a new raise that puts its tally over $1 billion (£850 million).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Oxford Science Enterprises collects $300M to offer spinouts 'scale-up capital'

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

Histogen files for bankruptcy; Barinthus Bio shares Ph1b/2 data for HPV treatment

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Ox­ford Sci­ence En­ter­pris­es col­lects $300M to of­fer spin­outs 's­cale-up cap­i­tal'

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Roche's Genen­tech touts la­bel ex­pan­sion for block­buster lung can­cer drug Ale­cen­sa

His­to­gen files for bank­rupt­cy; Barinthus Bio shares Ph1b/2 da­ta for HPV treat­ment

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Oxford Science Enterprises collects $300M to offer spinouts 'scale-up capital'

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

Histogen files for bankruptcy; Barinthus Bio shares Ph1b/2 data for HPV treatment

CSL Vifor proposes a marketing campaign to settle European Commission investigation